Article Content

Industry News

Integra LifeSciences Holdings Corporation, Plainsboro, New Jersey, has received FDA approval for the packaging of its new product, Integra Omnigraft Dermal Regeneration Matrix, which will allow its commercial release. The product's packaging is designed for ease of handling and application in the outpatient wound care setting. According to the manufacturer, the product is indicated for use in the treatment of partial-and full-thickness neuropathic diabetic foot ulcers that are greater than 6 weeks in duration, with no capsule, tendon, or bone exposed, when used in conjunction with standard diabetic ulcer care.


[black up pointing small triangle]Information: